RAPT Therapeutics (NASDAQ:RAPT) reported quarterly losses of $(0.63) per share. This is unchanged from the same period last year.
Related Posts
GM’s Total EV Sales In Q1 Can’t Even Match Tesla’s High-End Deliveries
General Motors sold 16,425 electric vehicles in the U.S. in the first three months of 2024, marking a drop of 20.5% year-on-year.
Gold Drops Below $2,000; Charles Schwab Earnings Top Views
U.S. stocks traded mostly flat midway through trading, following the release of economic data.
The Dow traded up 0.01% to 33,890.03 while the NASDAQ fell 0.18% to 12,101.34. The S&P 500, also fell, dropping, 0.11% to 4,133.25.
Alzheimer’s-Focused Cassava Sciences Faces Controversy as Key Collaborator Accused of Scientific Misconduct
Cassava Sciences Inc (NASDAQ: SAVA), the Alzheimer-focused firm, is facing further controversy as a recent investigation by the City University of New York (CUNY) has implicated neuroscientist Hoau-Yan Wang, a long-time collaborator of Cassava, in scientific misconduct related to 20 research papers.&nb